Bernhard, Jürg, Luo, Weixiu, Pavesi, Lorenzo, Parmar, Vani, Regan, Meredith M., Pagani, Olivia, Fleming, Gini F., Francis, Prudence A., Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Ribi, Karin, Walley, Barbara A., Colleoni, Marco, Burstein, Harold J., Tondini, Carlo, Pinotti, Graziella, Spazzapan, Simon, Ruhstaller, Thomas, Puglisi, Fabio. Elsevier; 2015. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

Ribi, Karin, Luo, Weixiu, Parmar, Vani, Tondini, Carlo, Kerbrat, Pierre, Perelló, Antonia, Neven, Patrick, Torres, Roberto, Lombardi, Davide, Puglisi, Fabio, Karlsson, Per, Ruhstaller, Thomas, Bernhard, Jürg, Colleoni, Marco, Coates, Alan S., Goldhirsch, Aron, Price, Karen N., Gelber, Richard D., Regan, Merideth M., Fleming, Gini F., Francis, Prudence A., Burstein, Harold J., Ciruelos, Eva, Bellet, Meritxell, Pavesi, Lorenzo, Lluch, Ana, Visini, Marilena. American Society of Clinical Oncology; 2016. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial.

Lee, Chee Khoon, Hudson, Malcolm, Simes, John, Ribi, Karin, Bernhard, Jurg, Coates, Alan. Biomed Central; 2018. When do patient reported quality of life indicators become prognostic in breast cancer?.

Pagani, Olivia, Regan, Meredith, Ciruelos, Eva, Stearns, Vered, Bonnefoi, Herve, Martino, Silvana, Geyer, Charles, Pinotti, Graziella, Puglisi, Fabio, Crivellari, Diana, Ruhstaller, Thomas, Winer, ERic, Walley, Barbara, Rabaglio-Poretti, Manuella, Maibach, Rudolf, Ruepp, Barbara, Giobbie-Herder, Anita, Price, Karen, Bernhard, Jurg, Luo, Weixiu, Ribi, Karin, Viali, Guiseppe, Coates, Alan, Fliming, Gini, Gelber, Richard, Goldhirsch, Aron, Francis, Prudence, Colleoni, Marco, Lang, Istvan, Gomez, Henry, Tondini, Carlo, Burstein, Harold, Perez, Edith. Massachusetts Medical Society; 2014. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Phillips, Kelly-Anne, Regan, Meredith, Abdi, Ehtesham, Domchek, Susan, Feng, Yang, Price, Karen, Coates, Alan, Gelber, Richard, Maruff, Paul, Boyle, Frances, Forbes, John F., Ahles, Tim, Ribi, Karin, Fleming, Gini, Bernhard, Jürg, Francis, Prudence A., Puglisi, Fabio, Bellet, Meritxell, Spazzapan, Simon, Karlsson, Per, Budman, Daniel, Zaman, Khalil. Nature Publishing; 2016. Adjuvant ovarian function suppression and cognitive function in women with breast cancer.

Fleming, Gini F., Saha, Poornima, Burstein, Harold J., Parmar, Vani, Torres, Roberto, Stewart, Josephine, Bellet, Meritxell, Perello, Antonia, Dane, Faysal, Moreira, Antonio, Vorobiof, Daniel, Nottage, Michelle, Regan, Meredith M., Price, Karen N., Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Colleoni, Marco, Pagani, Olivia, Francis, Prudence A., Walley, Barbara A., Ribi, Karin, Bernhard, Jurg, Luo, Weixiu, Gomez, Henry L.. American Society of Clinical Oncology; 2017. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials.